CASP3 and neoplasm: Meanwhile, the combination group exhibited intense immunoreactivity for caspase-3 and mild immunoreactivity for Ki67 and VEGF1, reflecting Gefitinib’s therapeutic activity in lowering tumor cell survival and neovascularization.